Skip to main content
Amoy Diagnostics Co.,Ltd. logo

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 ISIN · CNE1000034D3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,090 across all filing types
Latest filing 2018-07-27 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于公司2018年半年度募集资金存放与使用情况的专项核查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项核查报告" (special inspection report) by CITIC Securities regarding the half-year (2018) use and storage of funds raised by Xiamen Aide Biomedical Technology Co., Ltd. It details the actual amount of funds raised, their usage, balances, and compliance with regulatory requirements. The document includes detailed financial tables about the use of raised funds, bank accounts, and investment projects. It is a specialized audit or verification report focused on the use of raised capital for a half-year period, not a full annual report or interim financial report. It is not a general earnings release or investor presentation. The document is a standalone audit-type report on fundraising and fund usage compliance, consistent with an Audit Report / Information (AR) filing. The length (5591 characters) and content indicate it is the report itself, not just an announcement or certification. Therefore, the best classification is AR (Audit Report / Information). H1 2018
2018-07-27 Chinese
2018年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2018 年半年度报告全文" which translates to "2018 Semi-Annual Report Full Text." It contains detailed financial data, business overview, management discussion and analysis, risk factors, and other comprehensive information typical of an interim or quarterly report. The report period is specified as January 1, 2018 to June 30, 2018, confirming it covers a half-year period. The document includes financial statements, operational details, and management commentary, which are characteristic of an Interim / Quarterly Report (IR). The length of the document (15,000 characters) and the presence of substantive financial data and analysis confirm it is the report itself, not just an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2018
2018-07-27 Chinese
第一届董事会第十八次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolutions passed at the company's first board of directors' eighteenth meeting. It includes details about the meeting date, attendance, and voting results on the approval of the 2018 semi-annual report and a special report on the use of raised funds. The document references that the full semi-annual report is available on the regulatory disclosure website and in newspapers, indicating this document itself is not the report but an announcement of the board meeting decisions and related approvals. The document length is short (934 characters), and it serves as a formal disclosure of board resolutions rather than the full interim report. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and disclosures that do not fit other specific categories.
2018-07-27 Chinese
关于2018年半年度报告披露的提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (337 characters) stating that the company's 2018 half-year report has been disclosed on the official stock exchange website. It does not contain the actual half-year financial report or substantive financial data, but rather directs investors to where the report can be found. This fits the pattern of a Report Publication Announcement (RPA) rather than the Interim/Quarterly Report (IR) itself. The document also includes a formal statement from the board ensuring the accuracy of the disclosed information, which is typical in such announcements.
2018-07-27 Chinese
独立董事关于相关事项的独立意见
Audit Report / Information Classification · 95% confidence The document is an independent directors' opinion statement regarding specific matters such as related party transactions, external guarantees, and the use of raised funds during the first half of 2018. It references regulatory guidelines and confirms compliance but does not contain full financial statements or comprehensive financial performance data. The document is relatively short (613 characters) and serves as an independent opinion rather than a full audit or annual report. This type of document aligns best with an Audit Report / Information (AR) category, as it provides audit-related opinions and compliance verification without being a full annual report or interim financial report. H1 2018
2018-07-27 Chinese
第一届监事会第十四次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 14th meeting of the first Supervisory Board of Xiamen Aide Biological Pharmaceutical Technology Co., Ltd. It includes details about the meeting date, attendance, and voting results on the 2018 semi-annual report and a special report on the use of raised funds. The document confirms the supervisory board's review and approval of these reports but does not contain the reports themselves or detailed financial data. The document is short (981 characters) and serves as an official announcement of meeting resolutions and approvals rather than the reports or financial statements. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such announcements that do not fit other specific categories.
2018-07-27 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.